A Study on the Mutation of P53 and K-ras Gene in Colorectal Adenomas and Colorectal Carcinomas
Abstract
To investigate the incidence of P53 and K-ras gene mutation in colorectal adenomas and primary colorectal carcinomas. Methods There were 25 normal samples, 38 samples of colorectal adenoma, 78 samples of single primary colorectal cancer and 19 samples of multiple primary colorectal carcinomas (7 synchronous colorectal carcinomas and 12 metachronous colorectal carcinomas) collected in this study. With the analysis of clinico-pathologic features for each patient, exon 5-8 of P53 gene and codon 12-13 of K-ras gene of each sample were extended by real-time PCR. Multi-factor correlation analysis was carried out between the clinicopathologic features and the mutation of P53 and K-ras gene in colorectal adenoma and primary colorectal cancer. Results The P53 gene mutation is 0% (0/25)，44.8%（17/38），43.6%（34/78）and 42.1%（8/19）respectively in normal mucosa tissue, colorectal adenomas, single lesion and multiple lesion of primary colorectal carcinomas, while the proportion of K-ras gene mutation was 0%（0/25），18.4%（7/38），39.7%（31/78），47.4%（9/19）respectively. In our investigation there were obvious statistical differences as to the proportion of mutation of the P53 and K-ras gene between normal mucosa tissue and other three groups respectively (P<0.05）, while statistical differences as to the proportion of mutation of K-ras gene were found between colorectal adenomas group and single or multiple colorectal carcinoma group (P<0.05）. There was significant statistical difference between P53 and K-ras gene mutation in colorectal adenomas (P<0.05）. In addition, there were no statistical differences as to the proportion of mutation of the P53 and K-ras gene between the stageⅠ,Ⅱand well-differentiated ones of primary colorectal cancers and the stageⅢ Ⅳ and poorly-differentiated ones. There was no relationship between the age, gender, family history and tumor locations of the patients and the mutation of the P53 and K-ras gene. The stage and grade of differentiation of cancer was not the risky factor of the mutation of the P53 and K-ras gene in primary colorectal cancers. Conclusion The cancers. Conclusion results of this study not only suggest that mutation of P53 suppressor gene and K ras play a significant role in the procedure of colorectal tumorigenesis, but also indicate that the mutati on of P53 gene occurs earlier than K-ras mutation does during tumorigenesis.
Key words: Colorectal adenomas Multiple primary colorectal carcinomas P53, K-ras, Sequence, Mutation
Full Text:
PDFReferences
Heald RJ. Synchronous and metachronous carcinoma of the colon and rectum. Ann R Coll Surg Engl, 1990; 72 (3): 172- 174.
Hosaka S, Aoki Y.Akamatsu T, et al. Detection of genetic alterations in the p53 suppressor gene and the K-ras oncogene among different grades of dysplasia in patients with colorectal adenomas. Cancer, 2002; 94 (1): 219-227
Katsuhiko N.Shoko K, Natsumi I. et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology, 2009;137(5):1609-1620.
Herring JA, Udaya S, Cathie CH, et al. Multiple synchronous primaries of the gastrointestinal tract: a molecular case report. Cancer Letters, 1996; 110( 1-2); 1-9.
Smith G, Carey FA, Beattie J, el al. Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA,2002;99(14) ;9433- 9438.
Chang F, Syrjanen S, Kurvinen K, el al. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol, 1993 ;88(2): 174-186. Vogelstein B, Fearon ER, Hamilton SR. el al. Genetic alterations during colorectal tumor development. N Engl J Med, 1988;319(9);525-532.
Greenblatt MS, Bennett WP. Hollstein M, etal. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res, 1994 ;54(18) : 4855-4878. Motojima K, Urano T, Nagata Y. el al. Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. Ann Surg, 1993; 217 (2):138-143.
Pellegata NS. Sessa F. Renault B. et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994 ; 54 (6):1556-1560.
Yashiro M.Inoue T.Nishioka N, et al. Allelic imbalance at p53 and microsatellite instability are predictive markers for resistance to chemotherapy in gastric carcinoma. Ann Surg Oncol,2009; 16(10);2926-2935.
Ming SC. Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer, 1998;1 (1) ; 31-50.
Campomenosi P. Conio M. Bogliolo M. elal. p53 is frequently mutated in Barrett’s metaplasia of the intestinal type. Cancer Epidemiol Biomarkers Prev,1996;5(7):559-565.
Hollstein MC, Smits AM, Galiana C, el al. Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. Cancer Res, 1988;4 8 (18):5119-5123.
Lung M L, Chan W C, Zong YS, el al. p53 mutational spectrum of esophageal carcinomas from five different geographical in China. Cancer Epidemiol Biomarkers Prev, 1996;5(4):277-284.
Tada M, Omata M. Ohto M. el at. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res, 1990;50(4) ; 1121-1124.
Guo C, Liu QG, Zhang L, el al. Expression and clinical significance of p53. JunB and KAI1/CD82 in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2009;8(4):389-396.
Humphries A, Wright NA. Colonic crypt organization and Tumorigenesis. Naturev Rev,2008;8(6):415-424.
Mali P. Ye Z, Hommond HH,et al. Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Stem Cells,2008;26(8): 1998-2005.
Refbacks
- There are currently no refbacks.
